Protara Therapeutics (NASDAQ:TARA) Given Sell (D-) Rating at Weiss Ratings

Protara Therapeutics (NASDAQ:TARA - Get Free Report)'s stock had its "sell (d-)" rating reiterated by analysts at Weiss Ratings in a research report issued to clients and investors on Saturday,Weiss Ratings reports.Get Protara Therapeutics alerts:Protara Therapeutics Price PerformanceTARA stock traded down $0.06 during trading on Friday, reaching $5.10. The company had a trading volume of 409,192 shares, compared to its average volume of 561,198. Protara Therapeutics has a 52 week low of $1.96 and a 52 week high of $10.48. The company has a market cap of $196.77 million, a P/E ratio of -3.15 and a beta of 1.53. The business has a 50 day moving average of $4.00 and a 200 day moving average of $3.55. Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.08. Research analysts expect that Protara Therapeutics will post -3.32 earnings per share for the current year. Institutional Investors Weigh In On Protara TherapeuticsA number of institutional investors have recently made changes to their positions in TARA. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Protara Therapeutics during the second quarter valued at approximately $30,000. Quadrature Capital Ltd purchased a new stake in shares of Protara Therapeutics during the second quarter valued at approximately $35,000. JPMorgan Chase & Co. purchased a new stake in shares of Protara Therapeutics during the second quarter valued at approximately $46,000. Los Angeles Capital Management LLC purchased a new stake in shares of Protara Therapeutics during the second quarter valued at approximately $47,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Protara Therapeutics during the second quarter valued at approximately $49,000. Hedge funds and other institutional investors own 38.13% of the company's stock. Protara Therapeutics Company Profile (Get Free Report)Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.Featured ArticlesFive stocks we like better than Protara TherapeuticsWhat Are Earnings Reports?Tractor Supply Stock Looks Like a Buy-and-Hold WinnerHow to Use Stock Screeners to Find Stocks3 Stocks Well Below 52-Week Highs Poised for a Q4 ReboundInvesting In Preferred Stock vs. Common StockBig Banks Are Setting the Tone as Earnings Season Kicks OffThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Protara Therapeutics Right Now?Before you consider Protara Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.While Protara Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here